[Ip-health] Study on impact of CETA and USMCA on biosimilar and generic access in Canada

reedbeall at gmail.com reedbeall at gmail.com
Thu Nov 21 17:44:47 PST 2019

Dear colleagues,

For those interested in the area, please see our article on "How will recent
trade agreements that extend market protections for brand-name prescription
pharmaceuticals impact expenditures and generic access in Canada?" in the
journal Health Policy with coauthor Lorian Hardcastle, Fiona Clement, and
Aidan Hollis. The article is freely accessible until Jan 9 2020 at the
following link: https://authors.elsevier.com/a/1a5hDcP6n1eLo 

Best wishes,



Reed F. Beall, Ph.D.

Assistant Professor, Healthcare Policy

Community Health Sciences

Cumming School of Medicine & O'Brien Institute for Public Health

3280 Hospital Drive, TRW 3E46

Calgary, AB T2N 4Z6  Canada

Tel: 403.220.7452

Email: Reed.Beall at ucalgary.ca <mailto:Reed.Beall at ucalgary.ca> 

Web: http://reed-beall.squarespace.com <http://reed-beall.squarespace.com/>



More information about the Ip-health mailing list